/>iOn Monday, April 15, 2013, the United States Supreme Court will hear a challenge to Myriad’s patents on two isolated genes, BRCA 1 and BRCA 2. The two patented genes, when mutated, can put women at higher risk for breast and ovarian cancer. With the granted patents, Myriad has secured its position as the only place to go for testing of these genes, with a high price tag. Scientists, researchers and patients who believe the patents are blocking further research and limiting the availability of testing, are leading the challenge against Myriad’s patents.
Below is an in-depth look at patent eligibility and the challenge against Myriad, from Mercedes Meyer (may take a few moments to load):
